Navigation Links
Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
Date:1/30/2013

,944)Non-GAAP net income$64,273$57,750Non-GAAP net income per common share assuming dilutionGAAP net income per common share assuming dilution$0.50$0.95Non-GAAP items after tax per common share assuming dilution

$

0.73$

0.17Non-GAAP net income per common share assuming dilution$1.23$1.12Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.Nine Months Ended12/29/201212/31/2011Non-GAAP revenuesGAAP revenue$642,048$541,174Foreign currency effects

(44,440)(40,105)Non-GAAP revenue - constant currency$597,608$501,069Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring, transformation costs and contingent consideration income$64,273$57,750Foreign currency effects

(19,588)(13,293)Income tax associated with foreign currency effects

5,6613,628Non-GAAP net income - constant currency$50,346$48,085Non-GAAP net income per common share assuming dilutionNon-GAAP net income per common share assuming dilution, adjusted for restructuring, transformation costs and contingent consideration income$1.23$1.12Foreign currency effects after tax per common share assuming dilution

$

(0.27)$

(0.19)Non-GAAP net income per common share assuming dilution - constant currency$0.96$0.93 Restructuring, Transformation and Other Costs(Unaudited data in thousands) 

GAAP results include the following items which are excluded from adjust
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Haemonetics Provides Update on Hemerus Medical, LLC Acquisition
2. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
3. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
4. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
5. PAREXEL International Reports Second Quarter Fiscal Year 2013 Results
6. Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance
7. Danaher Reports Record Fourth Quarter 2012 Results
8. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
9. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
10. Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
11. Cepheid Reports Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- UBM Medica US announces that Diagnostic Imaging ... professionals, explored the complex situation regarding measuring the ... The shift from fee-for-service has left radiology at a ... determined in the new payment model . ... who recognized the complexity of the radiologist,s value: ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
Breaking Medicine Technology:Diagnostic Imaging Delves into Measuring the Radiologist's Value 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... TOULOUSE, France, May 15 Cerenis,Therapeutics SA ... compounds for the treatment of cardiovascular and,metabolic ... a Phase I,clinical trial for CER-002, one ... a peroxisome proliferator-activated receptor (PPAR),delta-specific agonist in ...
... Therapy that, Combined, with Aspirin, Causes Less Bleeding ... and Aspirin, According to a New Report ... Decision Resources, one of the,world,s leading research ... that Daiichi Sankyo/Eli Lilly,s Effient offers,improvement in patient ...
Cached Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
(Date:7/28/2014)... America Carotenoids & Antioxidants Market report defines and segments the ... forecast of revenue. This market is estimated to grow from ... at a CAGR of 7.1% from 2013 to 2018. , ... Antioxidants Market report to get an idea of the in-depth ... in the market, and is supported by various tables and ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- People with ... for obesity and diabetes, a new study suggests. ... that brown fat actually improves insulin sensitivity, blood sugar ... for overweight and obese people," Labros Sidossis, a professor ... at the University of Texas Medical Branch at Galveston, ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
... Dental Service Building for Early Childhood Oral Health at ... to provide 30,000 patient visits annually, SEATTLE, Nov. ... and Children,s Hospital and Regional Medical Center,today announced they ... dental disease with the development of a new pediatric ...
... and Reject ... Ramius, Opposition Slate, MONTVALE, ... mailed the following letter to all shareholders from,Lawrence Saper, Chairman ... Company,s Annual Meeting of Shareholders scheduled for,Thursday, December 20, 2007. ...
... Wash., Nov. 16 CellCyte Genetics,Corporation (the ... Tony,Colasin as its Director of Business Development ... licensing efforts. Tony Colasin was former ... From January 2001 to January 2007, he ...
... gave up as he,battled corporate investors as they took over ... him about greed and ethics,"isn,t the kind of thing you ... education to good use, pulling together an,experienced management team this ... juice drink for school-aged children. As co-founder and CEO ...
... Neutrogena(R), a worldwide leader,in the development of highly ... Diane Lane has signed on to be,an ambassador ... captivating and inspiring actress who personifies the,Neutrogena(R) brand ... her new,role, she will be featured in national ...
... rate between 0 and 2.6% (average 0.3%) in general population. ... tolerated by patients, causing a delay in medical consultation. Together ... with diagnosis and treatment of tinea of the nails. , ... the nails was observed in the Hospital del Mar Pediatric ...
Cached Medicine News:Health News:$5 M Gift Boosts Childhood Oral Health Care Offered by UW, Children's Hospital 2Health News:Datascope Mails Letter to Shareholders 2Health News:Datascope Mails Letter to Shareholders 3Health News:Datascope Mails Letter to Shareholders 4Health News:Datascope Mails Letter to Shareholders 5Health News:Datascope Mails Letter to Shareholders 6Health News:Datascope Mails Letter to Shareholders 7Health News:Datascope Mails Letter to Shareholders 8Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 2Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 3Health News:CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development 4Health News:Fruit 66 Creator Takes the High Road to Create a Healthy Drink for Students 2Health News:Oscar-Nominated Actress Signs on as Neutrogena(R) Brand Ambassador 2Health News:Tinea of the nails underdiagnosed in children 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: